The agreement between SickKids and Afference includes the licensed patents, technology, and intellectual property related to neuropeptides and sensory (pain) nerves, as well as future patents generated by the research program.
"I am able to state that our confidence to be able to translate our findings to human diabetes has distinctly grown..."
"...Our main clinical plan in both Type 1 and Type 2 diabetes patients is:Expand specific studies of patient responses to neuromodulatorsComplete regulatory approval process towards phase-1 trials in Type 1 and Type 2 diabetes patientsConduct neurological, non-invasive studies of afferent (pain) nerve sensitivitiesCollect patient blood samples for genetic sequencing studies of identified molecules suspected to play a role in human diabetes.We expect to begin intervention studies in 2008."
« Older 201 Stories by Anton Chekhov... | Exposition Universelle et Inte... Newer »
This thread has been archived and is closed to new comments
Buy a Shirt